171 related articles for article (PubMed ID: 38316993)
21. Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer.
Koujima T; Tazawa H; Ieda T; Araki H; Fushimi T; Shoji R; Kuroda S; Kikuchi S; Yoshida R; Umeda Y; Teraishi F; Urata Y; Mizuguchi H; Fujiwara T
Mol Ther Oncolytics; 2020 Jun; 17():107-117. PubMed ID: 32322667
[TBL] [Abstract][Full Text] [Related]
22. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
23. The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment.
Hashimoto Y; Tazawa H; Teraishi F; Kojima T; Watanabe Y; Uno F; Yano S; Urata Y; Kagawa S; Fujiwara T
PLoS One; 2012; 7(6):e39292. PubMed ID: 22720091
[TBL] [Abstract][Full Text] [Related]
24. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
[TBL] [Abstract][Full Text] [Related]
25. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
[TBL] [Abstract][Full Text] [Related]
26. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.
Fujiwara T; Kagawa S; Kishimoto H; Endo Y; Hioki M; Ikeda Y; Sakai R; Urata Y; Tanaka N; Fujiwara T
Int J Cancer; 2006 Jul; 119(2):432-40. PubMed ID: 16477640
[TBL] [Abstract][Full Text] [Related]
27. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
Huang P; Watanabe M; Kaku H; Kashiwakura Y; Chen J; Saika T; Nasu Y; Fujiwara T; Urata Y; Kumon H
Cancer Gene Ther; 2008 May; 15(5):315-22. PubMed ID: 18274558
[TBL] [Abstract][Full Text] [Related]
28. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
Yokoyama T; Iwado E; Kondo Y; Aoki H; Hayashi Y; Georgescu MM; Sawaya R; Hess KR; Mills GB; Kawamura H; Hashimoto Y; Urata Y; Fujiwara T; Kondo S
Gene Ther; 2008 Sep; 15(17):1233-9. PubMed ID: 18580968
[TBL] [Abstract][Full Text] [Related]
29. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
30. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
Mato-Berciano A; Raimondi G; Maliandi MV; Alemany R; Montoliu L; Fillat C
Oncotarget; 2017 Apr; 8(14):22700-22715. PubMed ID: 28186974
[TBL] [Abstract][Full Text] [Related]
31. Tumor-targeting adenovirus OBP-401 inhibits primary and metastatic tumor growth of triple-negative breast cancer in orthotopic nude-mouse models.
Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
Oncotarget; 2016 Dec; 7(51):85273-85282. PubMed ID: 27863373
[TBL] [Abstract][Full Text] [Related]
32. Telomerase-specific virotheranostics for human head and neck cancer.
Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
[TBL] [Abstract][Full Text] [Related]
33. A simple detection system for adenovirus receptor expression using a telomerase-specific replication-competent adenovirus.
Sasaki T; Tazawa H; Hasei J; Osaki S; Kunisada T; Yoshida A; Hashimoto Y; Yano S; Yoshida R; Kagawa S; Uno F; Urata Y; Ozaki T; Fujiwara T
Gene Ther; 2013 Jan; 20(1):112-8. PubMed ID: 22241176
[TBL] [Abstract][Full Text] [Related]
34. Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin).
Ouchi M; Kawamura H; Urata Y; Fujiwara T
Invest New Drugs; 2009 Jun; 27(3):241-5. PubMed ID: 18754077
[TBL] [Abstract][Full Text] [Related]
35. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
36. Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer.
Ishikawa W; Kikuchi S; Ogawa T; Tabuchi M; Tazawa H; Kuroda S; Noma K; Nishizaki M; Kagawa S; Urata Y; Fujiwara T
Mol Ther Oncolytics; 2020 Sep; 18():262-271. PubMed ID: 32728614
[TBL] [Abstract][Full Text] [Related]
37. Intraperitoneal Administration of p53-armed Oncolytic Adenovirus Inhibits Peritoneal Metastasis of Diffuse-type Gastric Cancer Cells.
Hori N; Tazawa H; Li Y; Okura T; Kikuchi S; Kuroda S; Ohara T; Noma K; Nishizaki M; Urata Y; Kagawa S; Fujiwara T
Anticancer Res; 2023 Nov; 43(11):4809-4821. PubMed ID: 37909979
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
39. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy.
Kojima T; Watanabe Y; Hashimoto Y; Kuroda S; Yamasaki Y; Yano S; Ouchi M; Tazawa H; Uno F; Kagawa S; Kyo S; Mizuguchi H; Urata Y; Tanaka N; Fujiwara T
Ann Surg; 2010 Jun; 251(6):1079-86. PubMed ID: 20485131
[TBL] [Abstract][Full Text] [Related]
40. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
Chen D; Huang L; Zhou H; Zhang Y
Front Immunol; 2021; 12():615089. PubMed ID: 33717103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
